Bristol Myers scraps gene therapy deal with uniQure for cardiovascular diseases
Bristol Myers Squibb is hitting the exit on a collaboration with a gene therapy biotech.
The Big Pharma company will no longer partner with uniQure on finding new treatments for cardiovascular diseases, the biotech reported to the SEC last week, following a rocky relationship that saw the pair break off an earlier agreement — before coming back to the table. The deal will officially terminate on Feb. 21, 2023.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.